MONITORING EVOLUTIONARY TRAJECTORIES IN NON-SMALL CELL LUNG CANCER TO IMPROVE TREATMENT OUTCOMES

Abstract

The expanding repertoire of treatment options in lung cancer is bringing into focus the need for improved ways to accurately monitor treatment responses and guide treatment decisions. Many cancers shed small amounts of DNA (ctDNA) into the bloodstream and changes in ctDNA levels have potential to be used as specific markers of response to cancer therapy. This project will evaluate novel strategies to directly guide treatment decisions in patients with lung cancer.

Related publications (1)

Custom workflows to improve joint variant calling from multiple related tumour samples: FreeBayesSomatic and Strelka2Pass.

S Hollizeck, SQ Wong, B Solomon, D Chandrananda, S-J Dawson

2021-09-01

SUMMARY: This work describes two novel workflows for variant calling that extend the widely used algorithms of Strelka2 and FreeBa..